Pchejetski et al. proposed that SPHK1 activity is a chemotherapy sensor, since prostate cancer cells sensitive to the chemotherapeutic drug camptothecin reduced SPHK1 levels after treatment (20). The gene discussed is SPHK1; the disease is prostate cancer.